• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    BeiGene inks $150M deal to follow cancer trail blazed by Amgen

    FIERCE BIOTECH

    BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor

    BUSINESSWIRE

    BeiGene & CLL Society Partner To Advance Test Before Treat Campaign

    BUSINESSWIRE

    BeiGene to Host Webcast on Data from ASH & SABCS on Dec. 16, 2024

    BUSINESSWIRE

    EC Approves BeiGene’s Tevimbra for Esophageal & Gastric Cancer

    BUSINESSWIRE

    BeiGene to Present at Upcoming Investor Conferences

    BUSINESSWIRE

    BeiGene defends Brukinsa from MSN`s generic threat until 2037

    FIERCE PHARMA

    BeiGene proposes new name, reaffirming oncology mission

    EUROPEAN PHARMACEUTICAL REVIEW

    BeiGene Proposes Name Change to BeOne Medicines for Cancer Mission

    BUSINESSWIRE

    BeiGene Announces Q3 2024 Financial Results and Corporate Updates

    BUSINESSWIRE

    BeiGene to Present at the Jefferies London Healthcare Conference

    BUSINESSWIRE

    BeiGene Highlights Hematology Portfolio at ASH 2024

    BUSINESSWIRE

    BeiGene Mourns Death of Beloved Board Member Donald Glazer

    BUSINESSWIRE

    BeiGene, ex-AstraZeneca exec faces investigation in China: reports

    FIERCE PHARMA

    Indaptus Signs Clinical Supply Agreement With BeiGene

    GLOBENEWSWIRE

    BeiGene Receives Positive CHMP Opinions For Trvimbra® Treatment

    BUSINESSWIRE

    BeiGene Highlights Waldenström’s Macroglobulinemia At IWWM 2024

    BUSINESSWIRE

    BeiGene launches PD-1 drug Tevimbra at 10% discount to Keytruda

    FIERCE PHARMA

    Anbogen Inks Deal With BeiGene For Colorectal Cancer Therapy

    BIOSPECTRUM ASIA

    BeiGene Appoints Shalini Sharp To Board Of Directors

    BUSINESSWIRE

    BeiGene Updates On FDA Vote On PD-1 Inhibitors

    BUSINESSWIRE

    FDA challenges broad use of PD-1 drugs in stomach cancer

    FIERCE PHARMA

    BeiGene Receives Israeli Approval For TEVIMBRA For Oesophageal Carcinoma

    BUSINESSWIRE

    AbbVie Sues BeiGene Over BTK Degrader Trade Secrets

    FIERCE BIOTECH

    AbbVie sues rival BeiGene over alleged theft of cancer therapy secrets

    REUTERS

    BeiGene Announces Updates to Commercial Leadership Team

    BUSINESSWIRE

    BeiGene Highlights TEVIMBRA Data In Lung And GI Cancers At ESMO 2024

    BUSINESSWIRE

    BeiGene Sponsors Leukemia & Lymphoma Society Campaign

    FIERCE PHARMA

    BeiGene To Present At Morgan Stanley Healthcare Conference

    BUSINESSWIRE

    BeiGene’s BGB-16673 Receives U.S. FDA Fast Track Designation for CLL/SLL

    BUSINESSWIRE

    BeiGene Reports Q2 2024 Results And Enters Next Global Growth Phase

    BUSINESSWIRE

    BeiGene Enters Next Phase of Global Growth with Announcement of Second Quarter 2024

    PRESS RELEASE

    BeiGene enhances biologic capability with new US facility

    PRESS RELEASE

    BeiGene Announces Appointment of Aaron Rosenberg as Chief Financial Officer

    BUSINESSWIRE

    BeiGene To Present BRUKINSA Plus Venetoclax CLL SLL Data

    BUSINESSWIRE

    Ensem’s partner BeiGene doses first five patients in first-in-human phase 1 tria

    PHARMABIZ

    BeiGene & NewBridge Pharmaceuticals FZ LLC Mutually Agree to Conclude BRUKINSA

    BUSINESSWIRE

    BeiGene to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

    BUSINESSWIRE

    BriaCell: BeiGene Supply Agreement For Bria-OTS First-In-Human Study

    GLOBENEWSWIRE

    Brukinsa® Cll Sll Profile: Differentiated Clinical Data At Asco

    BUSINESSWIRE

    Glenmark unit ties up with BeiGene to market cancer drugs in India

    MONEYCONTROL

    BeiGene looks at new partnerships,with full cancer pipeline & growing footprint

    ENDPTS

    BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024

    BUSINESSWIRE

    BeiGene Reports First Quarter 2024 Financial Results and Business Updates

    BUSINESSWIRE

    BeiGene earmarks $74M to build fourth facility in China

    ENDPTS

    BeiGene`s 2023 Responsible Business & Sustainability Report

    BUSINESSWIRE

    BeiGene Highlights New Hematology & Solid Tumor Data at ASCO 2024

    BUSINESSWIRE

    BeiGene`s Tislelizumab Approved in EU for Lung Cancer

    BUSINESSWIRE

    US FDA approves BeiGene`s esophageal cancer therapy

    REUTERS

    BeiGene looks beyond China as it secures API source, nears opening of US site

    ENDPTS

    BeiGene`s Biologic Tevimbra (tislelizumab) Receives Approval in the U.S.

    FDA

    First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia

    BUSINESSWIRE

    BeiGene bumps AbbVie, J&J from top lymphoma event sponsor spot

    FIERCE PHARMA

    US FDA approves expanded use of BeiGene`s blood cancer drug

    REUTERS

    BeiGene Announces FDA Accelerated Approval of BRUKINSA

    BUSINESSWIRE

    BeiGene to Present Clinical & Preclinical Data from Broad Portfolio and Pipeline

    BUSINESSWIRE

    BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib

    BUSINESSWIRE

    BeiGene to Present at Upcoming Investor Conferences

    BUSINESSWIRE

    BeiGene’s Biologics License Application for TEVIMBRA Accepted by FDA

    BUSINESSWIRE

    BeiGene Receives Positive CHMP Opinion for Tislelizumab

    BUSINESSWIRE

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.